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Conclusions: Real-life outcomes of PI-based dual ARV therapy appear
broadly favourable in clinical practice. The ongoing utility of this
paradigm in the advent of TAF and PI-sparing regimens is unclear.
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Introduction: Whilst access to ART is successfully expanding in Africa,
long-term outcomes remain poorly investigated. This study ad-
dressed the outcomes of introducing tenofovir (TDF) in place of
zidovudine (ZDV) or stavudine (d4T) among Ghanaian adults
receiving HIV care in the absence of routine virological monitoring
and determined the associated clinical and psychosocial dimensions.
Methods: The Hepatitis B Infection in Kumasi (HEPIK) study has
prospectively followed HIV/HBV co-infected adults since 2010. This
cross-sectional analysis comprised subjects that had previously
started ZDV or d4T plus lamivudine and efavirenz or nevirapine,
and at the time of HBV diagnosis (T0), replaced ZDV or d4T with TDF
in the absence of virological monitoring. A median of 7.9 (IQR 6.0
9.2) years after starting ART and 4.0 (3.84.1) years after introducing
TDF (T1, November 2015), patients were invited to attend for
assessment, including HIV-1 RNA load, and offered a researcher-
administered questionnaire about adherence (visual analogue scale
and targeted questions); socio-economic, social support and dis-
closure status; and physical and mental health. Plasma viral load at
T0 was determined retrospectively using stored (808C) samples.
Results: A total of 101/180 (56%) invited participants (66% females)
attended the T1 assessment. Of the remaining, 47 (26%) were no
longer contactable (]3 attempts), 17 (9%) declined to attend and 15
(8%) had died. At T1, mean age was 45 (99) years; 90% were still
receiving efavirenz (n87) or nevirapine (n4); 10% were on
lopinavir/ritonavir (LPV/r). CD4 counts were median 572 (383716)
cells/mm3. Suboptimal adherence was reported by 42% of partici-
pants; in univariable analysis, it was more prevalent among men
(pB0.01), those in a relationship (p0.02) and those with higher
socio-economic status (p0.04). Moderate-to-severe depression/
anxiety was reported by 27%; 64% described moderate-to-severe
physical distress. HIV-1 RNA was detectable (40 copies/mL) in
21%, and 1000 copies/mL in 14%, with median levels of 4.2 (2.1
5.1) log10 copies/mL. In univariable analysis, predictors of lack of
virological suppression comprised the CD4 cell count at diagnosis
(p0.03), T0 viral load (p0.05), suboptimal adherence (pB0.01),
lack of partner disclosure (pB0.01) and LPV/r use (p0.03). Lack of
virological suppression was also associated with lower T1 CD4 cell
counts (pB0.01). There was no association with socio-economic/
social support status, or physical/mental health.
Conclusion: One in five subjects receiving long-term ART showed
suboptimal virological suppression with reduced CD4 cell count
recovery. The findings highlight the importance of viral load testing at
key management time points, coupled with targeted interventions to
support adherence and facilitate partner disclosure.
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Introduction: Adherence to antiretroviral treatment (ART) in HIV
patients plays a crucial role for treatment success. Our study aimed
to identify reasons for non-adherence in a large HIV cohort, including
known subjects with difficulties in ART adherence.
Methods: A cross-sectional, non-interventional, multicentre adher-
ence study in treated HIV-infected patients from September 2014 to
April 2015 in Germany was performed after ethic committee’s
approval. Study physicians were asked to recruit patients from all
adherence levels and perform an adherence assessment for each
subject (good, unstable or poor adherence). Questionnaires based on
the SMAQ-MASRI-Hybrid [1] were given to the patient and treating
physician to evaluate factors associated with poor adherence.
Covariables of interest were age, sex, time since HIV diagnosis,
time on ART, current ART regimen, transmission route, comorbidity,
HIV-1 RNA viral loads (VLs) and CD4 cell count. Furthermore, specific
reasons for non-adherence were assessed. For statistical analysis,
extended Fisher’s exact test and KruskalWallis test were used.
Abstract P060Table 1. Overview of questionnaire items and correlation with adherence levels
‘‘Good adherence’’
(n162)
‘‘Unstable
adherence’’ (n36)
‘‘Poor adherence’’
(n17)
p-value (Fisher’s
exact test)
The ART intake reminds me of my disease n7 (4.3%) n4 (11%) n5 (29%) B0.01
I want to go out/I think my medication does not go well
with alcohol/party drugs
n3 (1.9%) n5 (14%) n4 (24%) B0.01
I’m afraid that others see me taking the ARTmedication n4 (2.5%) n4 (11%) n2 (12%) 0.019
I think that the ART dose is too high n3 (1.9%) n4 (11%) n1 (5.9%) 0.037
Sometimes the copayment fee to my ART is too much
for me/other financial reasons
n2 (1.2%) n3 (8.3%) n1 (5.9%) 0.037
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